Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan's syndrome and effects of GH replacement therapy.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

Despite several studies, present knowledge about the impact of GHD and GH replacement therapy (GHRT) on cognitive function is limited.

P300 event-related potential (ERP) application is a well-established neurophysiological approach in the assessment of cognitive functions including the updating of working memory content and the speed of stimulus evaluation.

GHD is a well-known feature of Sheehan's syndrome and cognitive changes due to GHD and the effects of GHRT remain to be clarified.

Who Took Part

The abstract describes 14 patients taking part.

PubMed indexes the participants as adults and middle-aged adults.

The study comprised 14 patients with Sheehan's syndrome (mean age, 49.5+/-7.8 years) and 10 age-, education- and sex-matched healthy controls.

With hormone replacement therapy, basal hormone levels other than GH were stable before enrollment and throughout the GHRT.

How the Study Was Run

The diagnosis of GH deficiency was established by insulin-tolerance test (ITT), and mean peak level of GH in response to insulin hypoglycemia was 0.77+/-0.35 mIU/l.

Initially baseline auditory ERPs in patients and controls were recorded at frontal (Fz), central (Cz), and parietal (P3 and P4) electrode sites.

During each session P300 amplitude and latency were measured.

What Was Measured

The subject headings attached to it are Acoustic Stimulation, Cognition, Cognition Disorders, Event-Related Potentials, P300, Evoked Potentials, Auditory, Hormone Replacement Therapy and Human Growth Hormone.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.